Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Gvoke Generic Name & Formulations
Legal Class
Rx
General Description
Glucagon 0.5mg/0.1mL, 1mg/0.2mL; soln for SC inj.
Pharmacological Class
Antihypoglycemic.
How Supplied
Prefilled syringes, autoinjectors (HypoPen)—1, 2; Kit (0.2mL)—1 (single-dose vial and syringe)
Manufacturer
Generic Availability
NO
Gvoke Indications
Indications
Severe hypoglycemia in diabetics.
Gvoke Dosage and Administration
Adults and Children
<2yrs: not established. Give by SC inj into lower abdomen, outer thigh, or outer upper arm. May repeat after 15mins if no response. 2–<12yrs (<45kg): 0.5mg; (≥45kg): 1mg. ≥12yrs: 1mg.
Gvoke Contraindications
Contraindications
Pheochromocytoma. Insulinoma.
Gvoke Boxed Warnings
Not Applicable
Gvoke Warnings/Precautions
Warnings/Precautions
Previously undiagnosed pheochromocytoma; risk of substantial increase in BP. If hypoglycemia develops after treatment, give oral or IV glucose. Conditions with insufficient hepatic glycogen (eg, starvation, adrenal insufficiency, chronic hypoglycemia); treat with glucose. Necrolytic migratory erythema (due to continuous infusion). Glucagonoma: if suspected, test prior to initiation and monitor during therapy. Pregnancy. Nursing mothers.
Gvoke Pharmacokinetics
See Literature
Gvoke Interactions
Interactions
May cause transient increase in BP and pulse with β-blockers. Antagonized by indomethacin. May potentiate warfarin.
Gvoke Adverse Reactions
Adverse Reactions
Adults: nausea, vomiting, inj site edema raised ≥1mm, headache; children: nausea, hypoglycemia, vomiting, headache, abdominal pain, hyperglycemia, inj site discomfort and reaction, urticaria; allergic reactions.
Gvoke Clinical Trials
See Literature
Gvoke Note
Not Applicable
Gvoke Patient Counseling
See Literature
